We have recently developed and introduced an Fc-optimized mAb (B7-H3-SDIE) that demonstrated improved NK cell reactivity against sarcomas, pancreatic cancer and acute myeloid leukemia compared to the Fc wildtype version bearing the same B7-H3 binder.43–45 Despite the mentioned recent advances in the application of anti-tumor mAbs, a major gap in ovarian cancer treatment is the lack of antibodies that redirect immune cells against tumor cells. Here, CD276 is linked to neoplasm.